​

Perspective Therapeutics (CATX) Stock Forecast, Price Target & Predictions

OverviewRevenueFinancialsChart

CATX Stock Forecast

Perspective Therapeutics (CATX) stock forecast, based on 11 Wall Street analysts, predicts a 12-month average price target of $11.75, with a high of $16.00 and a low of $7.00. This represents a 175.18% increase from the last price of $4.27.

- $4 $8 $12 $16 $20 High: $16 Avg: $11.75 Low: $7 Last Closed Price: $4.27

CATX Stock Rating

Perspective Therapeutics stock's rating consensus is Buy, based on 11 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 9 Buy (81.82%), 2 Hold (18.18%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 11 0 2 9 Strong Sell Sell Hold Buy Strong Buy

CATX Price Target Upside V Benchmarks

TypeNameUpside
StockPerspective Therapeutics175.18%
SectorHealthcare Stocks 15.45%
IndustryMedical Device Stocks32.39%

Price Target Trends

1M3M12M
# Anlaysts-35
Avg Price Target-$13.33$12.20
Last Closing Price$4.27$4.27$4.27
Upside/Downside-212.18%185.71%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 262121--15
Mar, 262121--15
Feb, 261111--13
Jan, 261121--14
Dec, 251121--14
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Mar 17, 2026Greg RenzaTruist Financial$12.00$5.09135.76%181.03%
Feb 19, 2026Biren AminPiper Sandler$16.00$5.03218.09%274.71%
Jan 30, 2026H.C. Wainwright$12.00$4.26181.69%181.03%
Nov 21, 2025David LaiUBS$7.00$2.12230.19%63.93%
Oct 10, 2025Jeet MukherjeeBTIG$14.00$4.20233.33%227.87%
Oct 24, 2024David DaiUBS$20.00$11.6971.09%368.38%
Oct 14, 2024Jeff JonesOppenheimer$22.00$12.6673.78%415.22%
Sep 25, 2024Nicole GerminoTruist Financial$21.00$12.2871.01%391.80%
Jul 25, 2024Alec StranahanBank of America Securities$24.00$12.8287.21%462.06%
Jun 18, 2024Jeff JonesOppenheimer$19.00$11.9359.26%344.96%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Feb 19, 2026Piper SandlerOverweightinitialise
Jan 30, 2026H.C. WainwrightBuyBuyhold
Nov 21, 2025UBSBuyBuyhold
Oct 10, 2025BTIGBuyinitialise
Sep 15, 2025OppenheimerOutperformOutperformhold
Jun 23, 2025B. RileyBuyBuyhold
Mar 07, 2025ScotiabankOutperforminitialise
Oct 24, 2024UBSBuyinitialise
Oct 14, 2024OppenheimerOutperformOutperformhold
Sep 30, 2024WedbushOutperforminitialise

Financial Forecast

EPS Forecast

Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28 Dec 29
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28Dec 29
Reported-$-0.27$-0.85$-1.23$-1.40----
Avg Forecast$-0.27$-0.14$-1.30$-1.20$-1.23$-1.33$-1.25$-1.31$0.39
High Forecast$-0.27$-0.12$-1.26$-0.99$-1.10$-0.96$-0.71$-0.99$0.49
Low Forecast$-0.27$-0.16$-1.37$-1.85$-1.33$-1.92$-2.01$-1.64$0.29
Surprise %-92.86%-34.62%2.50%13.82%----

Revenue Forecast

$0 $90M $180M $270M $360M $450M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28 Dec 29
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28Dec 29
Reported-$7.10M$1.43M------
Avg Forecast$10.03M$8.46M$7.86M$12.81M$1.07M$987.67K$834.04K$25.18M$339.79M
High Forecast$10.03M$8.90M$10.48M$12.81M$1.21M$1.15M$996.41K$30.08M$405.94M
Low Forecast$10.03M$8.02M$6.39M$12.81M$853.76K$823.06K$677.25K$20.45M$275.91M
Surprise %--16.03%-81.76%------

Net Income Forecast

$-150M $-110M $-70M $-30M $10M $50M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28 Dec 29
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28Dec 29
Reported-$-14.67M$-46.51M$-79.28M$-103.12M----
Avg Forecast$-37.89M$-3.75M$-35.19M$-32.12M$-78.03M$-121.21M$-87.65M$-84.07M$25.00M
High Forecast$-37.89M$-3.21M$-33.61M$-26.50M$-70.64M$-61.92M$-45.61M$-63.53M$31.32M
Low Forecast$-37.89M$-4.28M$-36.77M$-49.51M$-85.41M$-123.84M$-129.69M$-105.35M$18.89M
Surprise %-291.51%32.17%146.84%32.16%----

CATX Forecast FAQ

Is Perspective Therapeutics stock a buy?

Perspective Therapeutics stock has a consensus rating of Buy, based on 11 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 9 Buy, 2 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Perspective Therapeutics is a favorable investment for most analysts.

What is Perspective Therapeutics's price target?

Perspective Therapeutics's price target, set by 11 Wall Street analysts, averages $11.75 over the next 12 months. The price target range spans from $7 at the low end to $16 at the high end, suggesting a potential 175.18% change from the previous closing price of $4.27.

How does Perspective Therapeutics stock forecast compare to its benchmarks?

Perspective Therapeutics's stock forecast shows a 175.18% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the medical device stocks industry (32.39%).

What is the breakdown of analyst ratings for Perspective Therapeutics over the past three months?

  • April 2026: 13.33% Strong Buy, 80.00% Buy, 6.67% Hold, 0% Sell, 0% Strong Sell.
  • March 2026: 13.33% Strong Buy, 80.00% Buy, 6.67% Hold, 0% Sell, 0% Strong Sell.
  • February 2026: 7.69% Strong Buy, 84.62% Buy, 7.69% Hold, 0% Sell, 0% Strong Sell.

What is Perspective Therapeutics’s EPS forecast?

Perspective Therapeutics's average annual EPS forecast for its fiscal year ending in December 2026 is $-1.33, marking a -5.00% decrease from the reported $-1.4 in 2025. Estimates for the following years are $-1.25 in 2027, $-1.31 in 2028, and $0.39 in 2029.

What is Perspective Therapeutics’s revenue forecast?

Perspective Therapeutics's average annual revenue forecast for its fiscal year ending in December 2026 is $987.67K, reflecting a 0% decrease from the reported $0 in 2025. The forecast for 2027 is $834.04K, followed by $25.18M for 2028, and $339.79M for 2029.

What is Perspective Therapeutics’s net income forecast?

Perspective Therapeutics's net income forecast for the fiscal year ending in December 2026 stands at $-121M, representing an 17.54% increase from the reported $-103M in 2025. Projections indicate $-87.651M in 2027, $-84.075M in 2028, and $25M in 2029.